The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Tisa-cel in patients with primary CNS lymphoma
Matthew Frigault, MD, Harvard Medical School, Boston, MA, presents findings from a phase I/II trial (NCT02445248) assessing tisagenlecleucel (tisa-cel), a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, in patients with primary central nervous system (CNS) lymphoma (PCNSL). 12 patients were enrolled and have progressed on multiple lines of therapy including Bruton’s tyrosine kinase (BTK) inhibitors, autologous stem cell transplantation, and chemotherapy. A quarter of the cohort obtained a durable response and the tisa-cel was generally well tolerated. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
